A Medline search of research on pharmacotherapy was undertaken , and a previous systematic review on the evidence -based pharmacotherapy of panic disorder was up date d. Selective serotonin reuptake inhibitors remain a first-line pharmacotherapy of panic disorder , with the serotonin noradrenaline reuptake inhibitor venlafaxine also an acceptable early option .
Temporary co-administration of benzodiazepines can be considered .
For patients not responding to first-line agents several pharmacotherapy options are available , but there is a notable paucity of data on the optimal choice
The evidence -based pharmacotherapy of panic disorder continues to evolve .
This paper review s data on first-line pharmacotherapy , evidence for maintenance treatment , and management options for treatment-refractory patients .
The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects.
Regular physical activity is anxiolytic in both healthy subjects and patients with panic disorder . In contrast , acute exercise may induce acute panic attacks or increase subjective anxiety in patients with panic disorder more than in other people . The effects of quiet rest or an aerobic treadmill exercise ( 30 min at an intensity of 70 % of the maximal oxygen uptake , VO2max ) on cholecystokinin tetrapeptide ( CCK-4 ) induced panic attacks were studied in a crossover design in 12 patients with panic disorder and 12 matched healthy subjects . The effects of CCK-4 ( 25 microg in patients and 50 microg in control subjects ) were measured with the Acute Panic Inventory ( API ) score , comparing panic attack frequencies , total score , and subscores for anxiety and somatic symptoms . CCK-4-induced panic attacks were less frequent after prior exercise : they occurred in 15 ( 62.5 % ) subjects after rest ( 9 patients and 6 control subjects ) , but only 5 ( 20.8 % ) subjects after exercise ( 4 patients and 1 control subject ) . In both conditions , CCK-4 administration induced a significant increase in the total API score and the anxiety and somatic symptoms subsores . However , compared to prior rest , exercise result ed in a significantly reduced CCK-4-induced increase of the total API score and the anxiety subscore . In patients with panic disorder exercise increased the total API score and the somatic symptoms subscale but not the anxiety subscore .  Patients with panic disorder showed increased somatic but not anxiety symptoms after an acute bout of exercise .  Severity of CCK-4-induced panic and anxiety , on the other h and was reduced by exercise . These findings suggest that in addition to exercise training an acute bout of exercise may be used to reduce anxiety and panic attack frequency and intensity in panic disorder patients
A Medline search of research on pharmacotherapy was undertaken , and a previous systematic review on the evidence -based pharmacotherapy of panic disorder was up date d. Selective serotonin reuptake inhibitors remain a first-line pharmacotherapy of panic disorder , with the serotonin noradrenaline reuptake inhibitor venlafaxine also an acceptable early option .
Temporary co-administration of benzodiazepines can be considered .
For patients not responding to first-line agents several pharmacotherapy options are available , but there is a notable paucity of data on the optimal choice
The evidence -based pharmacotherapy of panic disorder continues to evolve .
This paper review s data on first-line pharmacotherapy , evidence for maintenance treatment , and management options for treatment-refractory patients .